Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

Clinical trial NCT06874946 · RECRUITING

Trial details

NCT number: NCT06874946
Sponsor: Peking University People's Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma T - Cell Lymphoma PTCL

Start date: 2025-02-14
Primary completion: 2026-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.